Bellevue Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Bellevue Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$254K	Buy	4,400 +5	+0.1%	+$287	0.12%	73
2026 Q1	$267K	Buy	4,395 +5	+0.1%	+$291	0.13%	67
2025 Q4	$237K	Buy	4,390 +6	+0.1%	+$289	0.08%	68
2025 Q3	$198K	Sell	4,384 -193	-4%	-$9.01K	0.09%	74
2025 Q2	$212K	Sell	4,577 -95	-2%	-$4.66K	0.1%	72
2025 Q1	$285K	Sell	4,672 -195	-4%	-$11.4K	0.16%	57
2024 Q4	$275K	Sell	4,867 -588	-11%	-$32.9K	0.14%	58
2024 Q3	$282K	Sell	5,455 -1,986	-27%	-$93.2K	0.15%	55
2024 Q2	$309K	Sell	7,441 -1,215	-14%	-$54.4K	0.17%	51
2024 Q1	$469K	Sell	8,656 -370	-4%	-$18.8K	0.27%	39
2023 Q4	$463K	Sell	9,026 -41	-0.5%	-$2.15K	0.41%	39
2023 Q3	$526K	Buy	9,067 +8	+0.1%	+$490	0.35%	31
2023 Q2	$579K	Buy	9,059 +107	+1%	+$7.17K	0.36%	29
2023 Q1	$621K	Sell	8,952 -2,278	-20%	-$161K	0.42%	28
2022 Q4	$802K	Sell	11,230 -944	-8%	-$71.2K	0.62%	21
2022 Q3	$857K	Buy	12,174 +6	+0%	+$435	0.67%	27
2022 Q2	$942K	Sell	12,168 -94	-0.8%	-$7.16K	0.68%	25
2022 Q1	$899K	Sell	12,262 -294	-2%	-$19.7K	0.55%	30
2021 Q4	$783K	Sell	12,556 -9,126	-42%	-$535K	0.46%	31
2021 Q3	$1.3M	Sell	21,682 -54	-0.2%	-$3.56K	0.79%	26
2021 Q2	$1.45M	Sell	21,736 -114	-0.5%	-$7.43K	0.89%	24
2021 Q1	$1.38M	Sell	21,850 -95	-0.4%	-$5.91K	0.86%	24
2020 Q4	$1.43M	Sell	21,945 -194	-0.9%	-$11.9K	0.88%	26
2020 Q3	$1.33M	Sell	22,139 -1,238	-5%	-$74.5K	0.93%	25
2020 Q2	$1.38M	Sell	23,377 -420	-2%	-$25.1K	1.41%	22
2020 Q1	$1.49M	Buy	23,797 +150	+0.6%	+$9.17K	1.55%	21
2019 Q4	$1.52M	Buy	+23,647	New	+$1.35M	1.17%	21

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bellevue Asset Management's BMY Position: Q2 2026 in Review

Bellevue Asset Management increased its Bristol-Myers Squibb (BMY) stake by 0.11% in Q2 2026, buying an estimated $287 and bringing the position to 4,400 shares worth $254K. The position accounts for 0.12% of the portfolio, ranked #73.

Bellevue Asset Management first reported a position in BMY in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.52M in Q4 2019. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Bellevue Asset Management held 4,400 shares of Bristol-Myers Squibb worth $254K as of Q2 2026.
Bellevue Asset Management bought 5 Bristol-Myers Squibb shares in Q2 2026, an estimated $287.
Bristol-Myers Squibb made up 0.12% of Bellevue Asset Management's portfolio in Q2 2026, its #73 holding.
Bellevue Asset Management first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 27 quarters since.
Bellevue Asset Management's Bristol-Myers Squibb position peaked at $1.52M in Q4 2019.
2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Bellevue Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.